TriangleNCT02780609 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percent
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- at 24 months
What was measured
Rate of participants' survival at time of evaluation.
Analysis population: All evaluable participants treated at dose level 3/RP2D.
Groups in this outcome
Phase 1 Dose Level 3 and Phase 2: Selinexor Plus HDM HCT
80 mg Selinexor given orally 2 to 3 hours prior to high dose-melphalan IV infusion Melphalan: Melphalan 100 mg/m\^2 IV over 30-45 minutes. Dexamethasone: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1). Autologous Hematopoietic Cell Transplantation (HCT): Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy. Fosaprepitant: Fosaprepitant at 150 mg IV on days -3 and -2.
| Group | Source count |
|---|---|
| Phase 1 Dose Level 3 and Phase 2: Selinexor Plus HDM HCT | 15 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase 1 Dose Level 3 and Phase 2: Selinexor Plus HDM HCT | 95.2 | Not reported | 70.7 | 99.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 70.7
- upper Limit
- 99.3
- value
- 95.2
- denoms
- counts
- group Id
- OG000
- value
- 15
- units
- Participants
- description
- Rate of participants' survival at time of evaluation.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- 80 mg Selinexor given orally 2 to 3 hours prior to high dose-melphalan IV infusion Melphalan: Melphalan 100 mg/m\^2 IV over 30-45 minutes. Dexamethasone: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1). Autologous Hematopoietic Cell Transplantation (HCT): Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy. Fosaprepitant: Fosaprepitant at 150 mg IV on days -3 and -2.
- id
- OG000
- title
- Phase 1 Dose Level 3 and Phase 2: Selinexor Plus HDM HCT
- param Type
- NUMBER
- population Description
- All evaluable participants treated at dose level 3/RP2D.
- reporting Status
- POSTED
- time Frame
- at 24 months
- title
- Overall Survival (OS)
- type
- OTHER_PRE_SPECIFIED
- unit Of Measure
- percent
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice